



PROGRAM

ANZGOG MEETINGS

WEDNESDAY 29TH MARCH

Time	Session	Room
9.00am-10.45am	Tumour Type Working Group Meetings All TTWG Members gather in the Mayfair 1 for welcome prior to breakout to individual rooms. - Ovarian - Cervical - Endometrial	Mayfair 1 Mayfair 2 Mayfair 3
10.45am - 11.00am	Morning Tea	Mayfair Foyer
11.00am - 12.30pm	Research Advisory Committee Meeting I	Mayfair 1
12.30pm - 1.30pm	Lunch	Mayfair Foyer
12.30pm - 3.00pm	ANZGOG Board of Directors Meeting	Grosvenor 1 & 2

SOCIAL PROGRAM

Welcome Reception: Bus Departs Grand Hyatt at 6.00pm

Wednesday, 29th March | 6.30pm - 9.00pm
Peter MacCallum Cancer Centre
305 Grafton Street, Melbourne

Conference Dinner

Friday, 31st March | 7.00pm - 11.00pm
The Residence Grand Hyatt



PURE SCIENCE SYMPOSIUM PROGRAM

WEDNESDAY 29TH MARCH

Time	Session	
1.30pm - 3.00pm	PURE SCIENCE SYMPOSIUM Session Chairs: Pam Pollock and Elaine Sanij Mayfair 1	GCP TRAINING Session Chair: Sue Brew Mayfair 2
1.30pm - 1.50pm	Kirsty Pringle <i>Novel insights into the renin-angiotensin system in endometrial cancer</i>	<p><i>Learn about the first change to GCP since its debut in 1996.</i></p> <p>Presenter: Eleanor Allan GCP Training Caledonian Clinical Training</p> <p>Bi-Annual Update Certificate Training For Study Coordinators, Nurses, Clinicians.</p>
1.50pm - 2.10pm	Liz Christie <i>Characterizing acquired chemoresistance in HGSC</i>	
2.10pm - 2.30pm	Clare Scott <i>Response and Resistance to PARP inhibitors: Beyond BRCA1/2</i>	
2.30pm - 2.40pm	Tracey O'Mara <i>Meta-analysis of genome-wide association data for 78,683 women by the Endometrial Cancer Association Consortium (ECAC) identifies eight new genetic risk regions for endometrial cancer</i>	
2.40pm - 2.50 pm	Claire Henry <i>Distinct patterns of expression of ROR1 and ROR2 in histological subtypes of epithelial ovarian cancer point to a role for the stroma in metastasis</i>	
2.50pm - 3.00pm	Q&A or Panel	
3.00pm - 3.30pm	Afternoon Tea	
3.30pm - 5.00pm	PURE SCIENCE SYMPOSIUM Session Chairs: Clare Scott and Nikola Bowden Mayfair 1	GCP TRAINING Presenter: Eleanor Allan Mayfair 2
3.20pm - 3.40pm	Caroline Gargett <i>Stem/progenitor cells in the normal endometrium and endometrial cancer</i>	
3.40pm - 4.00pm	Kylie Goringe <i>Exploring the genomic landscape of mucinous ovarian tumours</i>	
4.00pm - 4.20pm	Susan Jordan <i>Pooled analyses from the Epidemiology of Endometrial Cancer Consortium (E2C2): how do breast feeding and NSAID use influence endometrial cancer risk?</i>	
4.20pm - 4.30pm	Yu Yu <i>Syk activity determines invasiveness and its nuclear level is associated with poor survival in Ovarian Cancer</i>	
4.30pm - 4.50pm	Jason Lee <i>Inhibition of histone methyltransferases as novel targets for ovarian cancer therapy</i>	

CONFERENCE PROGRAM

THURSDAY 30TH MARCH

Time	Session
6.45am - 7.45am	Consumer led Health and Fitness Session 'Go step for Gynae' – gather in hotel outdoor forecourt, next to Reception.
8.30am - 8.45am	OFFICIAL WELCOME & ANZGOG UPDATE ALISON BRAND Savoy 1
8.45am - 10.00am	MAKING A DIFFERENCE FOR WOMEN WITH GYNAECOLOGICAL CANCER Session Chairs: Peter Sykes & Pearly Khaw Savoy 1
8.45am - 9.10am	Anil Sood <i>A framework for personalized approaches to ovarian cancer</i>
9.10am - 9.35am	David Tan <i>Ovarian clear cell carcinomas: Challenges and opportunities</i>
9.35am - 10.00am	Remi Nout <i>Combined modality treatment in rare gynaecological cancers</i>
10.00am - 10.30am	Morning Tea in the Exhibition Area
10.30am - 12.00pm	IMPROVING CLINICAL PRACTICE FOR WOMEN WITH CANCER Session Chairs: Sumi Ananda & Deb Neesham Savoy 1
10.30am - 10.50am	Kate Stern <i>Improving clinical practice in fertility preservation</i>
10:50am – 11.10am	Bradley Monk <i>International Game changing clinical trials- present and future</i>
11.10am - 11.30am	George Au-Yeung <i>Immunotherapy- promise, potential and pitfalls</i>
11.30am - 11.45am	Paul Cohen <i>Prognostic role of histologic tumour regression in patients receiving neoadjuvant chemotherapy for high-grade serous tubo-ovarian carcinoma</i>
11.45am - 12.00pm	Linda Mileshkin <i>Incidence of hypersensitivity reactions to paclitaxel with intravenous versus oral dexamethasone pre-medication</i>
12.00pm - 1.00pm	Lunch - Consumer Committee Bristol 1 / Quality Assurance Bristol 2/ Study Coordinators Connaught



CONFERENCE PROGRAM

THURSDAY 30TH MARCH

Time	Session
1.00pm - 2.30pm	TRIAL UPDATE Session Chairs: Linda Mileshkin, RAC Chair, Alison Davis, RAC Dep Chair Savoy 1 1. PARAGON- PI Michael Friedlander 2. OUTBACK- PI Linda Mileshkin 3. REZOLVE- PI Katrin Sjoquist 4. ECHO- PI Sandi Hayes presented by Martin Stockler 4. FEMME- PI Andreas Obermair presented by Vanessa Taylor 5. VELIA- PI Michael Friedlander 6. MOST- PI Michael Friedlander 7. PHAEDRA- PI Yoland Antill 8. STATEC- PI Alison Brand
2.30pm - 3.00pm	Afternoon Tea
3.00pm-4.00pm	REDUCING THE CANCER BURDEN Session Chairs: Peter Grant & Christopher Steer Savoy 1 Sponsored by: 
3.00pm - 3.20pm	Lisa Whop <i>Reducing the cancer burden in ATSI population</i>
3.20pm – 3.40pm	Julia Brotherton <i>Leading the cervical cancer prevention revolution: Australia's new cervical screening approach in the HPV vaccine eras</i>
3.40pm – 4.00pm	Rob Thomas <i>Cancer Pathway Development in Australia, Cancer Chief Advisor VIC Govt</i>
4.00pm – 4.30pm	OASIS PROGRAM TRIAL UPDATE Session Chairs: Michael Friedlander And Anna Defazio Savoy 1
4.00pm – 4.10pm	1. MOCCA- PI Michael Friedlander
4.10pm – 4.20pm	2. VIPS- PI Linda Mileshkin
4.20pm – 4.30pm	3. CYCLIN-E1- PI Danny Rischin
4.30pm - 5.00pm	TRANSLATIONAL ANZGOG TR-ANZGOG Session Chairs: Michael Friedlander And Anna Defazio
4.30pm – 5.00pm	Anna Defazio <i>More than a biobank!</i> <i>Enabling translational research for ANZGOG trials</i>
5.00pm – 5.45pm	Poster Viewing Session
5.45pm - 6.45pm	ANZGOG EVENING SESSION Session Chair: Michael Friedlander Practical guidance on the use of OLAPARIB in women with PSR BRCAM HGSO Michael Friedlander, Linda Mileshkin, Catherine Shannon
Evening Options	Free evening for dinner with friends and colleagues in Melbourne

CONFERENCE PROGRAM

FRIDAY 31ST MARCH



Time	Session
7.00am - 8.00am	ROCHE BREAKFAST: SATELLITE SYMPOSIUM IMPROVING OUTCOMES IN HGSOC: FROM TARGETED TRIALS TO TARGETED THERAPIES Chair: Dr George Au-Yeung, Peter MacCallum Cancer Centre The Speakers: Prof Rob Coleman MD Anderson and Prof Bradley Monk, University of Arizona Cancer Centre Savoy 3
8.30am - 10.15am	IMPROVING QUALITY OF LIFE Session Chairs: Sue Brew & Catherine Adams Savoy 1
8.30am - 9.45am	<i>Panel Session addressing 2 cases studies on Improving Quality of Life</i> Dr Janine Lombard – Calvary Mater Newcastle, Dr Viet Do – Westmead Hospital, Julia Martin – John Hunter Hospital, Kim Hobbs – Westmead Hospital Dr Bryony Simcock – Christchurch
9.45am - 10.00am	Penelope Webb <i>Lifestyle, side-effects and chemotherapy completion: results from the Ovarian Cancer Prognosis and Lifestyle (OPAL) Study</i>
10.00am - 10.15am	Yeh Chen Lee <i>The Risk of Endometrial Cancer for BRCA1 and BRCA2 Mutation Carriers</i>
10.15am - 10.45am	Morning Tea in the Exhibition Area
10.45am - 11.00am	Helene O'Neill and Consumer Group Presentation
11.00am - 1.00pm	TRIAL CONCEPTS Session Chairs: Linda Mileshkin & Alison Davis Savoy 1
11.00am - 11.15am	Rob Rome <i>Progress towards the establishment of an Australian Ovarian Cancer Clinical Quality Registry</i>
11.15am - 11.25am	Michael Friedlander (PI Linda Mileshkin) <i>Trials in Development- ICON 9</i>
11.25am - 11.35am	PI Kelly Phillip, Chen Lee <i>Trials in Development- STICS AND STONES (just received NHMRC Grant)</i>
11.35am - 11.45am	PI Linda Mileshkin <i>Trials in Development- Advaxis AIM2CERV</i>
11.45am - 11.50am	Questions
11.50am - 12.05pm	Tarek Meniawy <i>NEW CONCEPT 1: A phase II study of a PD-1/PD-L1 blockade in combination with neoadjuvant chemotherapy in newly diagnosed advanced ovarian cancer</i>
12.05pm - 12.20pm	Martha Hickey <i>NEW CONCEPT 2: WHAM (What Happens after Menopause)? Impact of risk-reducing bilateral salpingo-oophorectomy on non-cancer outcomes in high-risk women: A multicentre prospective study</i>
12.20pm - 12.35pm	Rachel Delahunty <i>NEW CONCEPT 3: Assessing Circulation Tumour DNA as a Predictive Biomarker in Type 2 Endometrial Cancer</i>
12.35pm - 12.50pm	Danny Rischin <i>NEW CONCEPT 4: Vascular disruption, anti-angiogenesis and immune checkpoint inhibition in high grade serous ovarian cancer</i>
12.50pm - 1.00pm	<i>NEW CONCEPTS: Questions and Discussion</i>
1.00pm - 2.00pm	Lunch in the Exhibition Area / STATEC Trial Meeting Connaught



Time	Session		
2.00pm - 5.00pm	SPECIALISED PROGRAM		
2.00pm – 3.30pm	Workshop 1: Concept Development Savoy 1	Workshop 2: Gynae Nurses Savoy 2	Workshop 3: Radiation Oncology Savoy 3
	Workshop 4: Consumers Bristol 1	Workshop 5: Study Coordinators Bristol 2	STATEC - Lymphedema Training Connaught
3.30pm - 4.00pm	Afternoon Tea		
4.00pm - 5.30pm	Workshop 1: Concept Development Savoy 1	Workshop 2: Gynae Nurses Savoy 2	Workshop 3: Radiation Oncology Savoy 3
	Workshop 4: Consumers Bristol 1	Workshop 5: Study Coordinators Bristol 2	PHAEDRA - trial meeting Connaught

CONFERENCE PROGRAM

SATURDAY 1ST APRIL

Time	Session
7.00am - 8.30am	RAC 2 Breakfast meeting Mayfair 2
8.45am - 10.15am	NEW HORIZONS - BENCH TO BEDSIDE Session Chairs: Paul Cohen & Jeff Goh Mayfair 1
	Sponsored by: 
8.45am - 9.05am	David Tan <i>Gene expression molecular subtypes in ovarian cancer: the next stop for precision medicine?</i>
9.05am - 9.25am	Anil Sood <i>Targeting the Undruggable: Advances and Obstacles in RNAi Therapy</i>
9.25am - 9.45am	Remi Nout <i>Introducing molecular prognostic factors for endometrial cancer into clinical practice - the PORTEC4a experience.</i>
9.45am - 10.00am	Tarek Meniawy <i>Higher PD-L1 expression predicts poor prognosis in patients with tubo-ovarian high-grade serous carcinoma treated with neoadjuvant chemotherapy</i>
10.00am - 10.15am	Nirmala Kampan <i>Serum IL-6 as a predictive biomarker for diagnosis of malignancy in high-grade serous ovarian carcinoma</i>
10.15am - 10.45am	Morning Tea in the Exhibition Area
10.45am - 11.45am	DEVELOPING STUDIES AND FUNDING WITH ANZGOG Session Chairs: Alison Brand & Raj Ali Mohan Mayfair 1
	Sponsored by: 
10.45am - 11.00am	Alison Brand <i>Developing Studies and Funding Options through ANZGOG</i>
11.00am - 11.10am	Philip Beale <i>Ovarian TTWG</i>
11.10am - 11.20am	Diana Adams <i>Endometrial TTWG</i>
11.20am - 11.30am	Anne Hamilton <i>Cervix TTWG</i>
11.30am - 11.45am	Peter Sykes <i>A review of cervical cancer cares in relation to screening history in New Zealand from 2008-2012</i>
11.45am - 12.45pm	DEBATE: SURGERY IS THE ULTIMATE SOLUTION TO ALL GYNAECOLOGICAL CANCER PROBLEMS Session Chairs: Alison Brand & Raj Ali Mohan Rob Coleman & Julie Lamont (affirmative) V Pearly Khaw & Andrew Dean (negative) Mayfair 1
12.45pm - 12.50pm	Thank you to delegates – ANZGOG Chair, Alison Brand
12.50pm - 1.30pm	Light Lunch available (<i>Buses depart from 1.30pm to Airport</i>)



CONSUMER EVENT

SATURDAY 1ST APRIL

Time	Session
2.00pm - 4.30pm	CONSUMER INFORMATION SESSION Collaborative Presentation by Ovarian Cancer Australia and ANZGOG Mayfair 1
	<i>Introduction</i>
	Tarek Meniawy <i>Immunotherapy as an Ovarian Cancer Treatment</i>
3.05pm - 3.30pm	Q & A
	Afternoon Tea
	Emma Burt <i>Participating in a Clinical Trial:</i>
	Linda Mileskin <i>Finding New Cancer Treatments & the Importance of Clinical Trials</i>
	Q & A
	Bronwyn Grout <i>Survivors Teaching Students: Saving Women's Lives</i>